Compare ETJ & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETJ | PCRX |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.9M | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | ETJ | PCRX |
|---|---|---|
| Price | $8.84 | $26.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.86 |
| AVG Volume (30 Days) | 175.6K | ★ 869.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.24 |
| Revenue Next Year | N/A | $9.53 |
| P/E Ratio | ★ N/A | $55.29 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $7.20 | $18.17 |
| 52 Week High | $8.47 | $27.64 |
| Indicator | ETJ | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 58.98 |
| Support Level | $8.77 | $25.56 |
| Resistance Level | $8.81 | $26.70 |
| Average True Range (ATR) | 0.08 | 0.94 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 96.87 | 59.77 |
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.